Osimertinib with or without Chemotherapy in <i>EGFR</i> -Mutated Advanced NSCLC

Abstract

First-line treatment with osimertinib-chemotherapy led to significantly longer progression-free survival than osimertinib monotherapy among patients with <i>EGFR</i>-mutated advanced NSCLC. (Funded by AstraZeneca; FLAURA2 ClinicalTrials.gov number, NCT04035486.).